Immunome
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Washington, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
18702 North Creek Pkwy Ste 100, Bothell,...Phone Number
(425) 939-7410Website
www.immunome.comRevenue
-Stock Symbol
IMNMIndustry
About Immunome
Immunome is a clinical-stage oncology company focused on developing innovative targeted therapies to improve outcomes for cancer patients. They specialize in antibody-drug conjugates (ADCs) and radioligand therapies, with a pipeline that includes both late-stage and preclinical candidates targeting various solid tumors. The company emphasizes a patient-centric approach in their drug development process, ensuring that transformative therapies are prioritized. Their team has extensive experience in the design and commercialization of advanced cancer treatments.Explore more
Immunome Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Immunome
Compare insights from companies similar to Immunome, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$132.7M
51-200
Public
$547.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Immunome Tech Stack
A closer look at the technologies used by Immunome
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immunome
Sign Up For FreeTo access detailed company insights
Immunome is a clinical-stage oncology company focused on developing innovative targeted therapies to improve outcomes for cancer patients. They specialize in antibody-drug conjugates (ADCs) and radioligand therapies, with a pipeline that includes both late-stage and preclinical candidates targeting various solid tumors. The company emphasizes a pat... Read More
